Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA.
, Minneapolis, MN, 55455, USA.
Curr Hematol Malig Rep. 2018 Feb;13(1):44-52. doi: 10.1007/s11899-018-0433-2.
Acute graft versus host disease (aGVHD) is a frequent cause of treatment-related mortality after allogeneic hematopoietic stem cell transplantation (alloHCT), with few effective treatment options beyond systemic steroids. Discovery of biomarkers for aGVHD may provide insight into the pathophysiology of aGVHD and suggest novel mechanisms for treatment.
We highlight biomarkers within innate immune activation, T-cell-mediated tissue damage, endothelial damage, dysbiosis, and poor wound healing that can be obtained prior to transplant, in the early transplant period, or at the onset of aGVHD. aGVHD biomarkers have predictive and prognostic utility but also suggest novel mechanisms of recipient tissue damage and impaired regenerative capacity. These mechanisms should be further studied and tested in therapeutic clinical trials to improve outcomes post-alloHCT.
异基因造血干细胞移植(alloHCT)后,急性移植物抗宿主病(aGVHD)是治疗相关死亡的常见原因,除全身类固醇外,治疗选择有限。aGVHD 生物标志物的发现可能有助于深入了解 aGVHD 的病理生理学,并为治疗提供新的机制。
我们重点介绍了移植前、移植早期或 aGVHD 发作时可获得的固有免疫激活、T 细胞介导的组织损伤、内皮损伤、微生态失调和伤口愈合不良的生物标志物。aGVHD 生物标志物具有预测和预后效用,但也提示了受者组织损伤和再生能力受损的新机制。这些机制应在治疗性临床试验中进一步研究和测试,以改善 alloHCT 后的结果。